First‐Line Osimertinib for <i>EGFR</i>‐Mutated Squamous Cell Lung Carcinoma: A Case Report
We encountered a rare EGFR-mutated squamous cell lung carcinoma that responded well to osimertinib. Osimertinib may be an option for the treatment of patients with EGFR-mutated squamous cell lung carcinoma.
Authors
- Eiji Takeuchi (ORCID: https://orcid.org/0000-0003-1541-9747)
- Kaori Nii
- Yoshio Okano
- Seiya Ichihara
- Naoki Kadota
- Tsutomu Shinohara (ORCID: https://orcid.org/0000-0002-1562-2043)
- Kazumasa Nanjo
- Shoji Sakiyama
- Hiroyuki Hino
- Keishi Naruse
- Hisanori Machida
- Nobuo Hatakeyama
- Yugo Matsumura
Institutions
- National Hospital Organization Kochi National Hospital (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1002/cnr2.70273
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00